John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Says Anthropic No Longer Seen as National Security Threat 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
WuXi AppTec Co., a leading drug development and manufacturing services provider, saw its shares climb sharply on Tuesday following the release of strong first-quarter earnings. The company, listed in both Hong Kong and Shanghai, reported impressive financial growth driven by rising demand across its core Contract Research, Development, and Manufacturing Organization (CRDMO) business.
For the January to March period, WuXi AppTec posted revenue of 12.44 billion yuan (approximately $1.7 billion), marking a 28.8% year-on-year increase. Net profit attributable to shareholders also grew significantly, rising 26.7% to 4.65 billion yuan. This solid performance boosted investor confidence, sending its Hong Kong-listed shares up by 15% to HK$144.8, the highest level recorded since December 2021.
The company’s strong quarterly results were largely fueled by exceptional growth in its chemistry segment, where revenue surged by 43.7%. This growth was supported by expanded capabilities in small-molecule development and manufacturing services, a key area within the global pharmaceutical outsourcing market. Increased operational efficiency and higher capacity utilization also contributed to improved profitability, highlighting WuXi AppTec’s ability to scale effectively amid growing demand.
In addition to chemistry services, the company reported steady gains in other business segments. Revenue from its testing division rose 27.4%, while the biology segment recorded a 10.1% increase. These gains reflect continued customer demand and the company’s strategic focus on emerging drug modalities, including nucleic acids and peptide-based therapies.
WuXi AppTec’s strong earnings performance underscores its position as a major player in the global biotech and pharmaceutical services industry. With ongoing expansion and rising demand for outsourced drug development solutions, the company remains well-positioned for sustained growth, making it a key stock to watch in the healthcare and life sciences sector.
